Skip to main content
Equibles
MD logo

MD · Pediatrix Medical Group, Inc. · Metrics

Track MD — free

Use MD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$31.44 +0.15 (+0.46%) Play latest call Q3 2026 earnings call transcript
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$2.44B
Shares
78.12M
Volume · Nov 9 36.88K Avg daily vol (3M) 753.2K

MD metrics

93 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$31.29
Market cap
$2.44B

Price action

23 metrics
Price change (1W)
+4.9%
Price change (30D)
+17.5%
Price change (3M)
+15.5%
Price change (6M)
+33.1%
Price change (YTD)
+46.3%
Price change (1Y)
+43.4%
Trailing year
Price change (5Y)
+9.1%
52-week high
$32.80
52-week low
$18.82
Change from 52-week high
-4.6%
Change from 52-week low
+66.3%
Annualized volatility
35.3%
Annualized volatility (3M)
28.2%
Implied volatility (30D)
46.6%
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.4
RSI (14D)
66.8
Price vs SMA 50
+14.2%
Price vs SMA 200
+29.8%
Avg volume (3M)
753,195
Relative volume
0.7
Average dollar volume
$20.56M

Company

3 metrics
Sector
Healthcare
Industry
Medical Care Facilities
Shares outstanding
78.12M

Valuation

12 metrics
P / E (TTM)
17.0
Trailing earnings · reciprocal yield 5.9%
PEG ratio
—
EV / revenue
1.4×
reciprocal yield 72.3%
EV / EBITDA
11.5×
reciprocal yield 8.7%
EV / EBIT
12.7×
reciprocal yield 7.8%
P / sales
1.2×
reciprocal yield 80.1%
P / book
2.9
reciprocal yield 34.8%
FCF yield
—
TTM · current market cap
Buyback yield
8.6%
P / FCF
—
P / operating cash flow
10.8
reciprocal yield 9.3%
Earnings yield
6.1%

Historical valuation

8 metrics
P / E historical average (3Y)
11.1×
reciprocal yield 9.0%
P / E historical average (5Y)
13.8×
reciprocal yield 7.3%
EV / revenue historical average (3Y)
0.9×
reciprocal yield 111.6%
EV / revenue historical average (5Y)
1.0×
reciprocal yield 103.7%
EV / EBIT historical average (3Y)
30.3×
reciprocal yield 3.3%
EV / EBIT historical average (5Y)
21.4×
reciprocal yield 4.7%
EV / EBITDA historical average (3Y)
14.7×
reciprocal yield 6.8%
EV / EBITDA historical average (5Y)
12.4×
reciprocal yield 8.0%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
8.6%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-10-29

Profitability

9 metrics
Gross margin
—
Operating margin
10.9%
Trailing 12 months
Net margin
7.7%
Gross profit (TTM)
—
Operating profit (TTM)
$212.58M
Net income (TTM)
$150.09M
Trailing 12 months
Diluted EPS (TTM)
$1.84
FCF margin
—
Effective tax rate
26.2%

Per share

11 metrics
Revenue per diluted share (TTM)
$23.81
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$2.59
EBITDA per diluted share (TTM)
$2.88
Net income per diluted share (TTM)
$1.83
Operating cash flow per diluted share (TTM)
$2.79
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.26
Book value per share
$10.43

Growth

11 metrics
Revenue growth YoY
+1.7%
Year over year
Net income growth YoY
-34.5%
Revenue (TTM)
$1.96B
Trailing 12 months
EPS growth YoY
-29.8%
Shares change YoY
-6.9%
Year over year · fewer shares
Revenue CAGR (3Y)
-1.0%
Revenue CAGR (5Y)
+2.0%
EPS CAGR (3Y)
+34.9%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
17.7%
Return on assets
7.0%
Debt / equity
0.7
Current ratio
1.3
EBITDA (TTM)
$236.36M
Free cash flow (TTM)
—
Quick ratio
1.3
Interest coverage
6.4
Net debt / EBITDA
1.1
Return on invested capital
14.1%
Trailing 12 months
Net cash
−$265.80M
Latest balance sheet
Cash & equivalents
$311.92M
Total assets
$2.14B
Total debt
$577.72M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$226.88M
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$21.28M
R&D / revenue
—
Stock compensation / revenue
1.1%

Ownership (13F)

9 metrics
13F filers
306
13F filer change QoQ
+7
Institutional ownership
107.1%
Conviction holders (share of 13F filers)
0.3%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+0.2%
Holder tenure
13.4
Price vs estimated holder cost
+40.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
32.8%

Short interest

3 metrics
Short interest
5.6%
Latest settlement · 5.8 days to cover
Days to cover
5.8d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 893949 CUSIP 58502B106 13F (30d) 149 filings 128 filers Visit website Investor relations